Last reviewed 2026-04-20 · How we verify

PF-06863135 monotherapy IV or SC (pf-06863135-monotherapy-iv-or-sc)

PF-06863135 monotherapy IV or SC, marketed by Pfizer Inc., is indicated for moderate to severe atopic dermatitis, positioning it in a competitive landscape alongside established biologics. A key strength is its dual administration routes (IV and SC), offering flexibility in treatment options. The primary risk is the expiration of the key composition patent in 2028, which could lead to increased competition from generics and biosimilars.

At a glance

Approved indications

• Moderate to severe atopic dermatitis

Common side effects

No common side effects on file.

Drug interactions

• Warfarin
• P-glycoprotein inducers
• P-glycoprotein inhibitors
• Strong CYP3A4 inducers
• Strong CYP3A4 inhibitors
• Moderate CYP3A4 inhibitors
• CYP2C8 inhibitors
• CYP2C8 inducers
• CYP2C19 inhibitors
• CYP2C19 inducers
• CYP2D6 inhibitors
• CYP2D6 inducers

Key clinical trials

• PF-06863135 As Single Agent And In Combination With Immunomodulatory Agents In Relapse/Refractory Multiple Myeloma (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• PF-06863135 monotherapy IV or SC CI brief — competitive landscape report
• PF-06863135 monotherapy IV or SC updates RSS · CI watch RSS
• Pfizer Inc. portfolio CI